Related Experiment Videos
Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia
S Jayabose1, O Tugal, C Sandoval
1Section of Pediatric Hematology-Oncology, New York Medical College, Valhalla 10595, USA.
Insights
Hydroxyurea therapy in children with sickle cell anemia significantly reduced vaso-occlusive crises (VOCs) and showed minimal toxicity. This treatment also improved hemoglobin levels in some patients, offering a potential therapeutic option.
Area of Science:
- Hematology
- Pediatric Medicine
- Pharmacology
Background:
- Sickle cell anemia is a severe inherited blood disorder characterized by abnormal hemoglobin, leading to vaso-occlusive crises (VOCs) and anemia.
- Current management strategies for sickle cell anemia aim to reduce the frequency and severity of complications, including VOCs and anemia.
Purpose of the Study:
- To investigate the efficacy of hydroxyurea in improving hemoglobin levels in pediatric sickle cell anemia patients.
- To evaluate the safety and toxicity profile of hydroxyurea treatment in this population.
- To determine the impact of hydroxyurea on the frequency of vaso-occlusive crises (VOCs) in children with sickle cell anemia.
Main Methods:
- An open-label pilot study involving 14 children with sickle cell anemia, divided into two groups based on VOC frequency and hemoglobin levels.
- Patients received hydroxyurea at doses ranging from 20 to 35 mg/kg/day.
- The frequency of VOCs and hemoglobin levels were compared before and during hydroxyurea therapy.
Main Results:
- Hydroxyurea therapy led to a significant reduction in the frequency of VOCs, decreasing from 2.5 to 0.87 per patient-year (a 65% decrease, p < 0.00001).
- Hemoglobin levels increased in some patients, with a median rise of 19 gm/L observed across all participants.
- Short-term hematologic toxicity was minimal, with only one patient discontinuing treatment due to nausea.
Conclusions:
- Hydroxyurea demonstrates potential in decreasing the severity of anemia and reducing the frequency of VOCs in children with sickle cell anemia.
- The drug exhibits minimal short-term hematologic toxicity, suggesting a favorable safety profile for this pediatric population.
Purpose:
This open-label pilot study was designed (1) to determine the effect of hydroxyurea on the hemoglobin level in children with sickle cell anemia, (2) to evaluate the toxicity of hydroxyurea, and (3) to assess any impact of hydroxyurea on the frequency of vaso-occlusive crises (VOCs).
Patients And Methods:
Ten children (group 1) with three or more VOCs of the extremities or two or more VOCs of the lungs (acute chest syndrome) in the preceding 12 months, and five children (group 2) with hemoglobin levels less than 70 gm/L were treated with hydroxyurea in doses of 20 to 35 mg/kg per day. The frequency of VOCs before hydroxyurea therapy was compared with the frequency during therapy, and the peak hemoglobin levels during hydroxyurea therapy were compared with the pretreatment values.
Results:
One patient in group 1 was removed from the study within 1 month because of nausea. Seven of the remaining nine patients in group 1 had a decrease in the frequency of VOCs. The number of VOCs per patient-year for all 14 patients decreased from 2.5 before hydroxyurea therapy to 0.87 during hydroxyurea therapy, a decrease of 65% (p < 0.00001). Two of five patients in group 2 had an increase in hemoglobin of 27 gm/L and 34 gm/L over the baseline. The median rise in hemoglobin was 19 gm/L (range, 7 to 37) for all 14 patients. Nine patients are still receiving hydroxyurea for a median period of 23 months (range, 18 to 59).
Conclusions:
Hydroxyurea decreases the severity of anemia in some patients, and it may decrease the frequency of VOC. Its short-term hematologic toxicity is minimal.